SL
INDV icon

Salomon & Ludwin’s Indivior Pharmaceuticals INDV Stock Holding History

Salomon & Ludwin’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.01K Sell
66
-773
-92% -$25.5K ﹤0.01% 1932
2025
Q4 		$30.4K Buy
+839
New +$25.6K ﹤0.01% 604

Other funds holding INDV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Salomon & Ludwin's INDV Position: Q1 2026 in Review

Salomon & Ludwin reduced its Indivior Pharmaceuticals (INDV) stake by 92% in Q1 2026, selling an estimated $25.5K and leaving 66 shares worth $2.01K. The position accounts for ﹤0.01% of the portfolio, ranked #1932.

Salomon & Ludwin first reported a position in INDV in Q4 2025 and has held it in 2 quarters since. The position peaked at $30.4K in Q4 2025. 289 funds tracked by Wall St. Rank hold INDV as of Q1 2026.

  • Salomon & Ludwin held 66 shares of Indivior Pharmaceuticals worth $2.01K as of Q1 2026.
  • Salomon & Ludwin sold 773 Indivior Pharmaceuticals shares in Q1 2026, an estimated $25.5K.
  • Indivior Pharmaceuticals made up ﹤0.01% of Salomon & Ludwin's portfolio in Q1 2026, its #1932 holding.
  • Salomon & Ludwin first reported a position in Indivior Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • Salomon & Ludwin's Indivior Pharmaceuticals position peaked at $30.4K in Q4 2025.
  • 289 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q1 2026.

Based on Salomon & Ludwin's 13F filing for Q1 2026, filed 11 May 2026.